L&G Healthcare Breakthrough UCITS ETF
ETF (UCITS compliant)
L&G Healthcare Breakthrough UCITS ETF
USD Accumulating ETF Class
ISINIE00BK5BC677
Price
TER0.49%
ISINIE00BK5BC677
Price
TER0.49%
Fund aim
The L&G Healthcare Breakthrough UCITS ETF (the "ETF") aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”).
Fund snapshot
- Long-term allocation
Long-term megatrend that we believe is radically transforming the way we live and work
- High growth potential
Aims to capture the outsized growth potential of the healthcare technology industry
- Leveraging industry expertise
An index tracking investment strategy that is supported by a team of healthcare technology experts
- Does it have a sustainable objective?
The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.
Fund facts
Fund size | $77.9m |
Base currency | USD |
Fund launch date | 2 Jul 2019 |
Domicile | Ireland |
Share class launch | 2 Jul 2019 |
Replication method | Physical - full replication |
Benchmark
ROBO Global® Healthcare Technology and Innovation Index TR
Index description
ROBO Global® Healthcare Technology and Innovation Index TR
The Index aims to track the performance of a basket of companies that are actively engaged in the healthcare technology value-chain.
The index is comprised of companies which are publicly traded on various stock exchanges around the world that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. Companies are included in the index receive a "HTEC Score" comprised of factors representing (1)the levels of revenue the company receives from innovative healthcare technologies, (2) the levels of investment the firm makes in healthcare technologies, (3) the market and technology leadership of the firm within the universe.
A company is only eligible for inclusion in the Index if it is of a sufficient size (determined by reference to the total market value of its shares) and it is sufficiently "liquid" ( a measure of how actively its shares are traded on a daily basis). Within the Index, companies are weighted according a modified HTEC-factor weighting scheme. The Index is rebalanced quarterly in March, June, September and December.
Index data
Provider | ROBO Global® |
Bloomberg code | HTECTR |
Reuters code | .HTECTR |
Type | Total Return |
Website | Go to website |
Performance
Performance scenarios
Example investment:10,000 USD
Scenarios | 1 year | (Recommended holding period) 5 years | |
---|---|---|---|
Minimum | There is no minimum guaranteed return. You could lose some or all of your investment. | ||
Stress scenario | What you might get back after costs | 1,430USD | 1,190USD |
Average return each year (%) | -85.66 | -34.71 | |
Unfavourable scenario | What you might get back after costs | 5,990USD | 5,810USD |
Average return each year (%) | -40.13 | -10.31 | |
Moderate scenario | What you might get back after costs | 11,940USD | 28,830USD |
Average return each year (%) | 19.38 | 23.58 | |
Favourable scenario | What you might get back after costs | 18,720USD | 52,770USD |
Average return each year (%) | 87.24 | 39.47 |
There is no minimum guaranteed return. You could lose some or all of your investment.
Portfolio breakdown
As at 31 Jan 2024
Top 10 constituents | 20.2% |
---|---|
Rest of Index | 79.8% |
No. of constituents in Index | 68 |
---|
Top 10 constituents (%)
Azenta | 2.2 |
Arrowhead Pharmaceuticals | 2.1 |
Irhythm Technologies | 2.1 |
Illumina | 2.1 |
Moderna | 2.0 |
Intuitive Surgical | 2.0 |
Catalent | 2.0 |
Revvity | 1.9 |
Lonza Group | 1.9 |
Stryker | 1.9 |
Sector (%)
Health Care | 97.0 |
Information Technology | 1.3 |
Consumer Staples | 0.9 |
Materials | 0.8 |
Top 10 constituents | 20.2% |
---|---|
Rest of Index | 79.8% |
No. of constituents in Index | 68 |
---|
Top 10 constituents (%)
Azenta | 2.2 |
Arrowhead Pharmaceuticals | 2.1 |
Irhythm Technologies | 2.1 |
Illumina | 2.1 |
Moderna | 2.0 |
Intuitive Surgical | 2.0 |
Catalent | 2.0 |
Revvity | 1.9 |
Lonza Group | 1.9 |
Stryker | 1.9 |
Sector (%)
Health Care | 97.0 |
Information Technology | 1.3 |
Consumer Staples | 0.9 |
Materials | 0.8 |
Currency (%)
USD | 85.9 |
EUR | 6.3 |
CHF | 4.6 |
GBP | 1.2 |
JPY | 1.0 |
HKD | 0.9 |
Country (%)
United States | 81.3 |
Switzerland | 4.6 |
Netherlands | 3.4 |
Italy | 1.7 |
Jersey | 1.6 |
Germany | 1.5 |
France | 1.5 |
Canada | 1.3 |
United Kingdom | 1.2 |
Other | 1.9 |
All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding. The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.
Fund managers
LGIM Index Fund Management Team
The Index Fund Management team comprises 25 fund managers, supported by two analysts. Management oversight is provided by the Global Head of Index Funds. The team has average industry experience of 15 years, of which seven years has been at LGIM, and is focused on achieving the equally important objectives of close tracking and maximising returns.
Sustainability
SFDR categorisation
Article 9The sustainable investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund seeks to achieve its investment objective by tracking the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The sustainable investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund seeks to achieve its investment objective by tracking the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The Fund follows the following sustainability-related investment strategy by tracking the Index that applies:
Literature
Document type
Prices
Pricing information
Price time | 16:00 EST (NY) |
Currency | USD |
Listings and codes
Listings
Exchange | Currency | Ticker | ISIN | Bloomberg | Reuters | Listing date | Trading hours (local) |
---|---|---|---|---|---|---|---|
Deutsche Börse Xetra | EUR | XMLH | IE00BK5BC677 | XMLH GY | DOCT.DE | 10/09/2019 | 09:00 - 17:30 |
London Stock Exchange | GBP | DOCG | IE00BK5BC677 | DOCG LN | DOCG.L | 02/07/2019 | 08:00 - 16:30 |
London Stock Exchange | USD | DOCT | IE00BK5BC677 | DOCT LN | DOCT.L | 02/07/2019 | 08:00 - 16:30 |
Borsa Italiana | EUR | DOCT | IE00BK5BC677 | DOCT IM | LGDOCT.MI | 10/09/2019 | 09:00 - 17:30 |
SIX Swiss Exchange | CHF | DOCT | IE00BK5BC677 | DOCT SW | DOCT.S | 05/06/2020 | 09:00 - 17:30 |
Codes
ISIN | IE00BK5BC677 |
SEDOL | - |
Bloomberg | DOCT |
MEX | - |
Dealing information
Issuer | Legal & General UCITS ETF Plc |
Depositary and Trustee | The Bank of New York Mellon SA/NV, Dublin Branch |
Securities regulator | Central Bank of Ireland |
Country registration
This share class is registered for sale in the following countries:
*The Fund is on the list of restricted collective investment schemes, but is not authorised or recognised by the Monetary Authority of Singapore (the “MAS”) and the Shares cannot be offered or marketed to retail clients.